{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:21:42Z","timestamp":1771856502641,"version":"3.50.1"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Hyperkalaemia (HK) is common in the emergency department (ED) and can cause life-threatening arrhythmias. Patiromer is a potassium binder whose role in acute HK management is uncertain; therefore, we investigated the efficacy and safety of patiromer as an adjunct to the standard of care treatment of HK in the ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A prospective, randomised, double-blind, placebo-controlled study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>16 ED sites across the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged \u226518 years treated at a participating ED who were found to have serum potassium \u22655.8\u2009mEq\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomised 1:1 to standard combination therapy (25\u2009g intravenous dextrose, 5 units intravenous insulin and 10\u2009mg albuterol) with either patiromer or placebo. The initial dose was given within 1\u2009hour of the potassium result, and the second dose 24 hours later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was net clinical benefit (NCB) at 6\u2009hours, defined as the change in number of potassium-lowering interventions minus change in serum potassium. Adverse events (AEs) were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study was terminated early and did not reach the prespecified sample size. Overall, 111 patients (53 patiromer and 58 placebo) were analysed. Mean (SD) age was 61.34 (15.21) years, 34% were female, 48% white and 22.5% received chronic haemodialysis. Mean baseline potassium was 6.5\u2009mmol\/L. NCB at 6\u2009hours was similar between patiromer and placebo (\u22120.6 vs \u22120.4; p=0.44). Potassium levels at 2, 4 and 6\u2009hours were similar between the groups (5.50 vs 5.70, 5.45 vs 5.65, 5.50 vs 5.60; patiromer and placebo (all p&gt;0.05)). The number of interventions per patient was similar (p&gt;0.05) between groups at each time point. The proportion of patients experiencing AEs was not significant between the patiromer and placebo groups (16.98% vs 32.76%; p=0.08).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No differences in efficacy were reported in this study, which was underpowered to detect statistical efficacy of patiromer over placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04443608\">NCT04443608<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-105103","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:35:30Z","timestamp":1771853730000},"page":"e105103","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): a randomised controlled trial in the emergency department"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04443608","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04443608","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zubaid","family":"Rafique","sequence":"first","affiliation":[{"name":"Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-7133","authenticated-orcid":false,"given":"Basmah","family":"Safdar","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyou","family":"Duanmu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Boone","sequence":"additional","affiliation":[{"name":"Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-130X","authenticated-orcid":false,"given":"Jason J","family":"Bischof","sequence":"additional","affiliation":[{"name":"Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Robinson","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Budden","sequence":"additional","affiliation":[{"name":"CSL Vifor, Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Budd","sequence":"additional","affiliation":[{"name":"Comprehensive Research Associates, LLC, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol M","family":"Quinn","sequence":"additional","affiliation":[{"name":"CSL Vifor, Glattbrugg, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Milliet","sequence":"additional","affiliation":[{"name":"CSL Vifor, Glattbrugg, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J","family":"Singer","sequence":"additional","affiliation":[{"name":"Emergency Medicine, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Soto","sequence":"additional","affiliation":[{"name":"Comprehensive Research Associates, LLC, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Peacock","sequence":"additional","affiliation":[{"name":"Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Comprehensive Research Associates, LLC, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2026022305351536000_16.2.e105103.1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15441\/ceem.16.194","article-title":"A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes","volume":"4","author":"Singer","year":"2017","journal-title":"Clin Exp Emerg Med"},{"key":"2026022305351536000_16.2.e105103.2","first-page":"S10","article-title":"Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure","volume":"23","author":"Rafique","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2026022305351536000_16.2.e105103.3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.8.917"},{"key":"2026022305351536000_16.2.e105103.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.132"},{"key":"2026022305351536000_16.2.e105103.5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MEJ.0000000000000691","article-title":"Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference","volume":"27","author":"Lindner","year":"2020","journal-title":"Eur J Emerg Med"},{"key":"2026022305351536000_16.2.e105103.6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07363"},{"key":"2026022305351536000_16.2.e105103.7","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"2026022305351536000_16.2.e105103.8","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026022305351536000_16.2.e105103.9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ekir.2020.02.1028","article-title":"Current Management of Hyperkalemia in Patients on Dialysis","volume":"5","author":"Bansal","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026022305351536000_16.2.e105103.10","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8871-2_1"},{"key":"2026022305351536000_16.2.e105103.11","article-title":"Emergency interventions for hyperkalaemia","volume":"2005","author":"Mahoney","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022305351536000_16.2.e105103.12","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1093\/eurheartj\/suy029","article-title":"Current treatment and unmet needs of hyperkalaemia in the emergency department","volume":"21","author":"Rafique","year":"2019","journal-title":"Eur Heart J"},{"key":"2026022305351536000_16.2.e105103.13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jemermed.2018.09.007","article-title":"Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL-ED): A Multicenter, Prospective, Observational Study","volume":"55","author":"Peacock","year":"2018","journal-title":"J Emerg Med"},{"key":"2026022305351536000_16.2.e105103.14","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp040300"},{"key":"2026022305351536000_16.2.e105103.15","doi-asserted-by":"crossref","DOI":"10.1002\/emp2.12572","article-title":"Hyperkalemia management in the emergency department: An expert panel consensus","volume":"2","author":"Rafique","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026022305351536000_16.2.e105103.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.10.008"},{"key":"2026022305351536000_16.2.e105103.17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","article-title":"Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study","volume":"35","author":"Laureati","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026022305351536000_16.2.e105103.18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026022305351536000_16.2.e105103.19","unstructured":"US Food and Drug Administration . Veltassa prescribing information. 2015. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205739s016lbl.pdf [Accessed May 2024]."},{"key":"2026022305351536000_16.2.e105103.20","unstructured":"US Food and Drug Administration . Sodium zirconium cyclosilicate prescribing information. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/207078s003lbl.pdf [Accessed May 2024]."},{"key":"2026022305351536000_16.2.e105103.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"2026022305351536000_16.2.e105103.22","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia","volume":"88","author":"Bushinsky","year":"2015","journal-title":"Kidney Int"},{"key":"2026022305351536000_16.2.e105103.23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.pcad.2020.09.007","article-title":"Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials","volume":"63","author":"Pi\u00f1a","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2026022305351536000_16.2.e105103.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"2026022305351536000_16.2.e105103.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"2026022305351536000_16.2.e105103.26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/acem.13868","article-title":"Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study","volume":"27","author":"Rafique","year":"2020","journal-title":"Acad Emerg Med"},{"key":"2026022305351536000_16.2.e105103.27","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2581912","article-title":"Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial","volume":"57","author":"McArthur","year":"2025","journal-title":"Ann Med"},{"key":"2026022305351536000_16.2.e105103.28","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/phar.2038","article-title":"A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency","volume":"37","author":"LaRue","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2026022305351536000_16.2.e105103.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071311","article-title":"Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study","volume":"13","author":"Rafique","year":"2023","journal-title":"BMJ Open"},{"key":"2026022305351536000_16.2.e105103.30","first-page":"487","article-title":"Potassium Disorders: Hypokalemia and Hyperkalemia","volume":"92","author":"Viera","year":"2015","journal-title":"Am Fam Physician"},{"key":"2026022305351536000_16.2.e105103.31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ekir.2017.10.009","article-title":"Treatment of Hyperkalemia With a Low-Dose Insulin Protocol Is Effective and Results in Reduced Hypoglycemia","volume":"3","author":"McNicholas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026022305351536000_16.2.e105103.32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nefroe.2023.12.002","article-title":"Consensus document on the management of hyperkalemia","volume":"43","author":"Ortiz","year":"2023","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"2026022305351536000_16.2.e105103.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1250-0","article-title":"Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England","volume":"20","author":"Horne","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026022305351536000_16.2.e105103.34","unstructured":"Food and Drug Administration . Select committee on GRAS subsatnces (SCOGS) opinion: cellulose, microcrystalline cellulose. 1973. Available: https:\/\/wayback.archive-it.org\/7993\/20171031063405\/https:\/\/www.fda.gov\/Food\/IngredientsPackagingLabeling\/GRAS\/SCOGS\/ucm261287.htm [Accessed Nov 2024]."},{"key":"2026022305351536000_16.2.e105103.35","doi-asserted-by":"publisher","DOI":"10.1177\/1074248416629549"},{"key":"2026022305351536000_16.2.e105103.36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/acem.13954","article-title":"Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE)","volume":"27","author":"Peacock","year":"2020","journal-title":"Acad Emerg Med"},{"key":"2026022305351536000_16.2.e105103.37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/OAEM.S478693","article-title":"A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department","volume":"16","author":"Goriacko","year":"2024","journal-title":"Open Access Emerg Med"},{"key":"2026022305351536000_16.2.e105103.38","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.acepjo.2025.100158","article-title":"Outcomes and Resource Utilization in Hyperkalemic Emergency Department Patients Treated With Patiromer or Sodium Zirconium Cyclosilicate","volume":"6","author":"Peacock","year":"2025","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026022305351536000_16.2.e105103.39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/13696998.2021.1965389","article-title":"Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients","volume":"24","author":"Desai","year":"2021","journal-title":"J Med Econ"},{"key":"2026022305351536000_16.2.e105103.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226844","article-title":"Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization","volume":"15","author":"Desai","year":"2020","journal-title":"PLoS One"},{"key":"2026022305351536000_16.2.e105103.41","unstructured":"World Medical Association . WMA declaration of Helsinki \u2013 ethical principles for medical research involving human subjects. Fortaleza, Brazil: Last amended by the 64th WMA General Assembly, 2013."},{"key":"2026022305351536000_16.2.e105103.42","unstructured":"ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R2), current step 4 version. 2016."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-105103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:35:45Z","timestamp":1771853745000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-105103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-105103"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-105103","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}